Trial Profile

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary) ; Empagliflozin
Indications Cardiovascular disorders
Focus Pharmacodynamics
Acronyms EXCEED-BHS3

Most Recent Events

07 Mar 2023 Status changed from recruiting to completed.
04 Apr 2022 Primary endpoint (Difference in the percentage change in flow mediated dilation (FMD)) has been met as per results presented at the 71st Annual Scientific Session of the American College of Cardiology
04 Apr 2022 Results (N=110) presented at the 71st Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com